Definium Therapeutics said its LSD-derived therapy eased generalized anxiety disorder symptoms in the first of two planned Phase 3 studies. The randomized trial enrolled 214 patients receiving a single dose of DT120 or placebo, with company-reported outcomes positioning the program as the second major catalyst in under two months after an earlier depression Phase 3 success.